Premium Cabozantinib API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Cabozantinib / Cabozantinib S-Malate (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Multi-Receptor Tyrosine Kinase (RTK) Inhibitor / Antineoplastic Agent

Indications: Renal Cell Carcinoma (RCC), Hepatocellular Carcinoma (HCC), Medullary Thyroid Cancer (MTC)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Cabozantinib distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Cabozantinib is an orally bioavailable, small-molecule Active Pharmaceutical Ingredient (API). In oncology and antineoplastic pharmacology, it is classified as a multi-receptor tyrosine kinase inhibitor (TKI). For pharmaceutical manufacturers developing advanced targeted cancer therapies, this API represents a critical component in managing aggressive and treatment-resistant malignancies.

The pharmacological efficacy of Cabozantinib stems from its ability to concurrently inhibit multiple receptor tyrosine kinases implicated in tumor growth, pathological angiogenesis, and metastasis. While many legacy TKIs target a single pathway, Cabozantinib competitively binds to and inhibits a broad spectrum of receptors, including MET (hepatocyte growth factor receptor), VEGFR-1, -2, and -3 (vascular endothelial growth factor receptors), AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2.

In the pathophysiology of renal cell carcinoma and hepatocellular carcinoma, the upregulation of MET and AXL pathways frequently provides tumor cells with an escape mechanism against standard VEGFR inhibitors, leading to drug resistance. By blocking these secondary pathways alongside VEGFR, Cabozantinib directly disrupts the tumor microenvironment, suppressing tumor cell proliferation, inducing apoptosis, and starving the malignancy of its blood supply.

For formulation scientists, integrating this API allows for the production of highly potent oral oncology therapeutics. In commercial manufacturing, the active ingredient is most commonly utilized in its malate salt form (Cabozantinib S-Malate) to formulate 20 mg, 40 mg, and 60 mg film-coated tablets, or 20 mg and 80 mg hard gelatin capsules.

Sourcing Cabozantinib in Pakistan: Morgan’s Supply Network

Manufacturing advanced oncology formulations requires a highly secure, traceable, and uninterrupted raw material pipeline. Procuring High-Potency Active Pharmaceutical Ingredients (HPAPIs) for local commercial manufacturing involves navigating complex international logistics, extended lead times, and stringent regulatory compliance protocols. Sourcing Cabozantinib Pakistan through Morgan’s localized distribution network systematically mitigates these supply chain risks.

Morgan supplies pilot-scale and commercial-scale quantities sourced from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines for active pharmaceutical ingredients. Partnering with Morgan as your primary supply vendor secures the following operational provisions for your oncology manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), detailed impurity and degradation profiles, and comprehensive stability data to support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables and customs bottlenecks. Whether executing a routine batch or scaling up a high-volume Cabozantinib api Pakistan procurement order, we ensure your commercial batch schedules and production timelines are met without raw material shortages.
• Batch-to-Batch Uniformity: Every API delivery provided by Morgan includes a rigorously verified Certificate of Analysis (CoA) from the source manufacturer. We guarantee that our supplied batches maintain consistent chemical purity, controlled moisture limits, and a specific particle size distribution (PSD) for predictable behavior during high-shear blending, wet granulation, and tablet compression processes.

Technical Specifications for QA & R&D

The Cabozantinib API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• CAS Number: 849217-68-1 (Free Base) / 1140909-48-3 (S-Malate Salt)
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C28H24FN3O5 (Free Base)
• Molecular Weight: 501.51 g/mol (Free Base)
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling, salt selection, and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Cabozantinib is classified as a High-Potency Active Pharmaceutical Ingredient (HPAPI) and a targeted cytotoxic agent. Facilities processing this compound must enforce the highest levels of occupational exposure limits (OEL) to protect personnel and prevent cross-contamination.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, protected from excessive heat and ambient humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must operate within dedicated, high-containment oncology suites. Processing requires advanced Personal Protective Equipment (PPE), including powered air-purifying respirators (PAPR) or supplied-air systems, double-layered chemical-resistant nitrile gloves, and full-body protective Tyvek suits. Dispensing, micronization, milling, and compounding stages must be executed exclusively within negative-pressure containment isolators (glove boxes) or restricted access barrier systems (RABS).

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.